Beaver Run Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2002



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Gene-Based Vaccines: Mechanisms, Delivery Systems and Efficacy (D3)


Organizer(s) Margaret A. Liu and Jay A. Berzofsky
April 10—15, 2002
Beaver Run Resort • Breckenridge, Colorado USA
Abstract Deadline: Dec 10, 2001
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Feb 19, 2002

Summary of Meeting:
Gene-based vaccines (both plasmid- and vector-based) are considered a most promising approach for making both prophylactic and therapeutic vaccines against a number of infectious diseases and cancer. These vaccines can induce the cytolytic T cell responses thought to be critical for many viral and parasitic diseases and cancer more effectively than protein-based or killed-organism vaccines, yet do not have the potential risk that attenuated viruses may have. In addition, they may have a number of other technological advantages for vaccines needed on a global scale. However, to date, a number of fundamental issues need to be solved, including increasing the potency of the vaccines by understanding the mechanisms of DNA uptake and antigen presentation, and determining how to harness the unexpected immunostimulatory effects of DNA itself. This meeting will provide the opportunity to bring together scientists from a variety of disciplines (microbiology, virology, cell biology, vaccinology, gene therapy, oncology, infectious diseases, polymer chemistry) to address the fundamental cellular mechanisms involved, within the context of the greater immunological issues.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


WEDNESDAY, APRIL 10

16:00—19:00
Registration

Third Floor Foyer
18:15—19:15
Welcome

Third Floor Foyer
19:15—19:30
Orientation

Peaks 4-5
19:30—21:00
Keynote Session
Meeting has ended...abstracts no longer viewable online.

Peaks 4-5
Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA
DNA Vaccines: Immunological Mechanisms and Clinical Implications

Gary J. Nabel, Sanofi, USA
Vaccines for Ebola Virus and Acutely Emerging Infections


THURSDAY, APRIL 11

07:00—08:00
Breakfast

Peaks 6-12
08:00—11:00
Mechanisms of Gene Uptake by Cells and Antigen Processing
Meeting has ended...abstracts no longer viewable online.

Peaks 4-5
Jonathan W. Yewdell, NIAID, National Institutes of Health, USA
Factors in the Rational Design of CD8+ T Cell Inducing-Vaccines

* Harriet L. Robinson, GeoVax Inc., USA
Multiprotein DNA Priming and Recombinant Poxvirus Boosting for an AIDS Vaccine

Hildegund C.J. Ertl, Wistar Institute, USA
A Novel Viral Vector for Vaccination

Smita Nair, Duke University School of Medicine, USA
Cancer Immunotherapy with Tumor RNA Transfected Dendritic Cells.

Charles J. Hackett, NIAID, National Institutes of Health, USA
Short Talk: NIH Strategic Plan for Biodefense Research

09:20—09:40
Coffee Break

Foyer
11:00—13:00
Poster Setup

Peaks 1-3
13:00—22:00
Poster Viewing

Peaks 1-3
14:30—16:30
Workshop 1: Mechanisms and Use of Gene-Based Vaccines for Augmentation and Modulation of Type of Immune Responses

Peak 4-5
* Heather L. Davis, Pfizer Inc., Canada

Bartek T. Zuber, Swedish Orphan Biovitrum, SOBI, Sweden
DNA Prime Followed by Protein/CpG Boost Induces Potent Immune Responses to HIV-1 RT in Primates

Marcos Timon, Mologen Molecular Medicines, Spain
DNA Immunisation with Minimalistic Expression Constructs

Cristina Ferrone, Memorial Sloan Kettering, USA
IL-12:IgG Fusion Gene as a Molecular Adjuvant for Xenogeneic DNA Vaccines

Pavel Pisa, Karolinska Hospital, Sweden
Linkage of PSA Gene to hsp65 or hsp70 Genes - Implications for Naked DNA Vaccination

Jason Rice, University of Southampton Hospitals Trust, UK
Critical Components of a DNA Fusion Vaccine Able to Induce Protective Cytotoxic T Cells Against a Single Epitope of a Tumor Antigen

Joanna Kirman, Malaghan Institute of Medical Research, New Zealand
Differential Immunotherapeutic Effects Against Tuberculosis by Different CpG Motifs

Arya Biragyn, NIA, National Institutes of Health, USA
Pro-Inflammatory Chemokine or beta-Defensin Mediated Targeting of Immature DC Elicit Potent Antitumor Protective and Therapeutic Immunity. Implication for the Development of AIDS and Other Vaccines

16:30—17:00
Coffee & Snacks Available

Foyer
17:00—19:00
Second-Generation Plasmid Delivery Systems
Meeting has ended...abstracts no longer viewable online.

Peaks 4-5
Danuta B. Kozbor, Roswell Park Cancer Institute, USA
Adjuvanted Mucosal Delivery of Microparticle- and Liposome-Formulated DNA Vaccines

* Jeffrey B. Ulmer, GSK Vaccines, USA
DNA Vaccine Delivery Technologies for Enhanced Potency

William F. Swain, Powderject Vaccines, Inc., USA
Clinical Experience with a PowderJect DNA Vaccine for Hepatitis B Virus Administered by Particle-Mediated Delivery to Skin

19:00—20:00
Welcome Mixer

Peaks 1-3
20:00—22:00
Poster Session 1

Peaks 1-3

FRIDAY, APRIL 12

07:00—08:00
Breakfast

Peaks 6-12
08:00—11:00
Vector-Based Gene Delivery Systems
Meeting has ended...abstracts no longer viewable online.

Peaks 4-5
* Peter Liljestrom, Karolinska Institute, Sweden
DNA/RNA-Based Replicon Vectors for Vaccination

Bernard Moss, National Institutes of Health, USA
Engineering Poxvirus Vectors

John M. Polo, Chiron Corporation, USA
Alphavirus Replicon Vectors for Vaccine Applications

Marcelo B. Sztein, University of Maryland, USA
Bacterial Plasmid Delivery Systems

W. Martin Kast, University of Southern California, USA
Short Talk: Eradication of Established Tumors by Vaccination with Venezuelan Equine Encephalitis Virus Replicon Particles Delivering HPV 16 E7 RNA

09:20—09:40
Coffee Break

Foyer
11:00—13:00
Poster Setup

Peaks 1-3
13:00—22:00
Poster Viewing

Peaks 1-3
14:30—16:30
Workshop 2: Mechanisms of Antigen Processing and Presentation

Peak 4-5
* Jonathan W. Yewdell, NIAID, National Institutes of Health, USA

Helen A. Andersson, University of Texas MD Anderson Cancer Center, USA
Targeting of Genetic Vaccines for Enhanced Degradation and Immune Presentation

Milcho Mincheff, George Washington University, USA
Inhibition of Protein Translocation to the ER Targets them for Proteasomal Degradation: Implications on Development of Vectors for Immunotherapy

Jens Leifert, The Scripps Research Institute, USA
The HIV-1 Protein Transduction Domain in DNA Vaccines

Chien-Fu Hung, Johns Hopkins University, USA
Improving Vaccine Potency Through Intercellular Spreading and Enhanced MHC Class I Presentation of Antigen

Ted M. Ross, University of Georgia, USA
Enhanced Immunogenicity Elicited to HIV-1 or Influenza by DNA Vaccination with Murine or Human C3d Fusions

Wolfgang Eugen Schmitt, German Cancer Research Center ( DKFZ), Germany
Genetical Engineered Tumor Vaccines: Surface Displayed Anti-phOx scFv as Anchor for Immunstimulatory Antibodies

Rana A.K. Singh, Baylor College of Medicine, USA
Role of T Cell Antagonism and Original Antigenic Sin in Genetic Immunization

16:30—17:00
Coffee & Snacks Available

Foyer
17:00—19:00
Mechanisms of Nucleotide Sequence Motif-Based Immunostimulation
Meeting has ended...abstracts no longer viewable online.

Peaks 4-5
* Eyal Raz, University of California, San Diego, USA
The Adjuvanticity of Microbial Products: Their Role in Cross Presentation and Cross Priming

Arthur M. Krieg, Checkmate Pharmaceuticals, USA
Shifting from Th2 to Th1 with Immune Stimulatory CpG DNA

Dennis M. Klinman, U.S. Food and Drug Administration, USA
Role of CpG Stimulatory and G-Rich Inhibitory Motifs in Innate and Cognate Immune Responses

19:00—20:00
Welcome Mixer

Peaks 1-3
20:00—22:00
Poster Session 2

Peaks 1-3

SATURDAY, APRIL 13

07:00—08:00
Breakfast

Peaks 6-12
08:00—11:00
Mechanisms of Mixed Modality Gene-Based Vaccination
Meeting has ended...abstracts no longer viewable online.

Peaks 4-5
Barney S. Graham, NIAID, National Institutes of Health, USA
Current Approaches to HIV Vaccine Development

* Jay A. Berzofsky, NCI, National Institutes of Health, USA
Approaches to Enhance Vaccine Efficacy

Barry T. Rouse, University of Tennessee, USA
Maximizing the Extent and Duration of Mucosal Immunity Using DNA Encoding Antigens and Immunomodulators

Andrew J. McMichael, Oxford University, UK
Immunogenicity and Mechanisms of a DNA and MVA Prime Boost HIV Vaccine in Humans

Michael A. Brehm, University of Massachusetts Medical School, USA
Short Talk: T Cell Immunodominance and Maintenance of Memory as a Consequence of Exposure to Unexpectedly Cross-Reactive Pathogens

09:20—09:40
Coffee Break

Foyer
11:00—13:00
Poster Setup

Peaks 1-3
13:00—22:00
Poster Viewing

Peaks 1-3
14:30—16:30
Workshop 3: Delivery Systems

Peak 4-5
* Dominique Kaiserlian, INSERM-U851, France
The Buccal Mucosa: As a Suitable Route for Targeting Epithelial DC with DNA or Protein Vaccines

Sean N. Tucker, Vaxart, Inc., USA
Salivary Gland Genetic Vaccination Promotes Robust Systemic and Mucosal Immune Responses

Kristina K. Peachman, U.S. Military HIV Research Program, USA
Induction of Th1, Th2 and Mucosal Responses to HIV Antigens by Trancutaneous Immunization

Joel R. Haynes, LigoCyte Pharmaceuticals, Inc., USA
Vectors Encoding CT and LT are Potent Adjuvants for Particle-Mediated DNA Vaccines

Olivier Vidalin, GlaxoSmithKline, UK
Modulation of Immune Responses Using a Carrier Protein Delivered by Gene-Gun DNA Immunisation

Kris Huygen, Pasteur Institute, Belgium
Improved Tuberculosis DNA Vaccines by Formulation in Cationic Lipids

Jill Glasspool-Malone, Union Institute and University, USA
Electroporation Greatly Enhances Intradermal DNA Vaccintation

Paul A. Hamblin, GlaxoSmithKline Research & Development, UK
Induction of a MUC1-Specific Immune Response by Particle Mediated Intradermal Delivery

16:30—17:00
Coffee & Snacks Available

Foyer
17:00—19:00
Effect of Co-Delivery of Cytokines and Co-Stimulatory Molecules
Meeting has ended...abstracts no longer viewable online.

Peaks 4-5
James P. Allison, University of Texas MD Anderson Cancer Center, USA
More is Less: New Insights into the Mechanisms of Negative Costimulation by CTLA-4 and its Manipulation in the Enhancement of T Cell Responses

* David B. Weiner, University of Pennsylvania School of Medicine, USA
Next Generation DNA Vaccines for HIV-1

Dan H. Barouch, Harvard Medical School/Beth Israel Deaconess Medical Center, USA
DNA Vaccine-Elicited Cytotoxic T Lymphocyte Responses and Protection Against Clinical AIDS in Rhesus Monkeys

19:00—20:00
Welcome Mixer

Peaks 1-3
20:00—22:00
Poster Session 3

Peaks 1-3

SUNDAY, APRIL 14

07:00—08:00
Breakfast

Peaks 6-12
08:00—11:00
Clinical Efficacy of Gene-Based Vaccines
Meeting has ended...abstracts no longer viewable online.

Peaks 4-5
* Britta E. Wahren, Karolinska Institute, Sweden
Clinical Efficacy of Gene-Based HIV Vaccines

Robert E. Johnston, Global Vaccines, Inc., USA
Alphavirus Replicon Vaccines for Lentiviruses

Stephen L. Hoffman, Sanaria, USA
Clinical Trials of Malaria DNA Vaccines: What Has Been Learned?

Freda K. Stevenson, Southampton University Hospitals Trust, UK
Therapeutic Cancer DNA Vaccines Encoding Fusion Proteins

Mary Lynne Hedley, TESARO, Inc., USA
Short Talk: The Use of Antigens Delivered in Polymer Formulated pDNA to Elicit Immune Responses in Humans

09:20—09:40
Coffee Break

Foyer
14:30—16:30
Workshop 4: Targeted Delivery and Functional Genomics Approaches for Gene-Based Vaccines

Peak 4-5
* Joel R. Haynes, LigoCyte Pharmaceuticals, Inc., USA

Jason P. Gardner, GlaxoSmithKline, USA
A Potent Alphavirus Replicon Particle Vaccine Encoding PSMA for Immunotherapy of Prostate Cancer

Isabelle P. Hunziker, The Scripps Research Institute, USA
Coxsackievirus B3: Analysis of Recombinant RNA Vaccines for Their Protective Effects Against a Lethal Virus Challenge in Mice

Richard J. Anderson, University of Oxford, UK
Enhanced T Cell Responses Following Heterologous Prime-Boost Immunization Using Attenuated Poxviruses

Robert Coffin, Biovex Limited, UK
VHS Deleted HSV Efficiently Transduces Dendritic Cells while Maintaining Dendritic Cell Activation: Development of Vectors for Cancer and Infectious Disease Immunotherapy

Stuart D. Perkins, Dstl Chemical and Biological Sciences, UK
Enhanced Distribution of Antigens Encoded by DNA Vaccines

Mary Lynne Hedley, TESARO, Inc., USA

Helen Garmory, Dstl Chemical and Biological Sciences, UK
DNA Vaccines Encoding the Yersinia pestis V Antigen: Optimisation of Promoter, Codon Usage and Delivery Route

16:30—17:00
Coffee & Snacks Available

Foyer
17:00—18:20
Issues for Gene-Based Vaccines
Meeting has ended...abstracts no longer viewable online.

Peaks 4-5
* Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA

J. Lindsay Whitton, The Scripps Research Institute, USA
DNA Immunization: the Pros & Cons of Antigen Targeting

Connie S. Schmaljohn, US Army Medical Research Institute of Infectious Disease, USA
DNA Vaccines for Potential Agents of Biowarfare of Bioterrorism

18:20—19:00
Closing Address
Meeting has ended...abstracts no longer viewable online.

Peaks 4-5
Phil K. Russell, US Department of Health & Human Services, USA
Vaccines for Civilian Biodefense

19:00—20:00
Welcome Mixer

Peaks 1-3
20:00—23:00
Entertainment

Peaks 1-3

MONDAY, APRIL 15

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 CA94576-01




We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676